Table 4.
Main effects estimates of NSAID and RAS exposure
| Exposure | IRR (95% CI) | IRD (95% CI)a |
| NSAID | ||
| Weighted analysis in cohort B | 1.24 (1.06 to 1.44) | 5.09 (1.13 to 9.05) |
| Weighted analysis in cohort C | 1.28 (1.07 to 1.53) | 5.07 (1.03 to 9.11) |
| Multivariable regression in cohort A | 1.23 (1.11 to 1.37) | 5.59 (2.51 to 8.66) |
| RAS inhibitors | ||
| Weighted analysis in cohort B | 1.18 (1.00 to 1.39) | 4.06 (0.34 to 7.78) |
| Weighted analysis in cohort C | 1.25 (1.02 to 1.54) | 4.71 (0.81 to 8.61) |
| Multivariable regression in cohort A | 1.09 (0.98 to 1.22) | 2.27 (−0.23 to 4.77) |
NSAID, nonsteroidal anti-inflammatory drug; RAS, renin-angiotensin system; IRR, incident rate ratio; IRD, incidence rate difference.
a
AKI events/1000 person days.